Biocompatibles to evaluate Bead Block for uterine fibroids
This article was originally published in Clinica
UK company Biocompatibles International has told Clinica it is soon to begin clinical evaluation of its Bead Block embolisation therapy for treating uterine fibroids. The Farnham, Surrey-based company said a non-US clinical trials programme is scheduled to commence later this year.
You may also be interested in...
AMAG outlines plans for retrospective real-world evidence studies, and possibly a new placebo-controlled trial with a primary endpoint of preterm birth <32 weeks, in a filing opposing the Center for Drug Evaluation and Research’s proposal to withdraw the drug.
The leading Korean pharma firm’s oral, third-generation EGFR-TKI is approved in the country, providing a new option for patients with advanced NSCLC and increasing hopes for global approvals given an ongoing global Phase III combination trial led by partner J&J.
DePuy Synthes expects its Velys robotic-assisted system to be cost-effective, easy-to-use and to be well-suited for use in ambulatory surgery centers.